Official Journal of
East European Branch of
CardiOncology Society
Joanna Kufel-Grabowska

Otrzymano/Received: 11.05.2015. Zaakceptowano/Accepted: 16.09.2015.

Leczenie chorych na zaawansowanego raka piersi dużymi dawkami doksorubicyny liposomalnej po wcześniejszej terapii klasyczną doksorubicyną

Therapy with liposomal doxorubicin in patients with advanced breast cancer after treatment with classical doxorubicin OncoReview 2015; 3(19): 103-108. DOI: 10.5604/20828691.1171777.
STRESZCZENIE

Breast cancer is the most common female cancer in the world and in Poland. The improvement of diagnostic and therapeutic methods has led to patients’ longer life expectancy. It has also made breast cancer a chronic disease, increasing the risk of late side effects of oncological therapy. More cardiovascular diseases are diagnosed in patients over 65 with an oncological history than in those without it and therefore much effort must be made to maximise effectiveness of the therapy with as few side effects as possible. The article presents two breast cancer patients treated with big doses of liposomal doxorubicin with a good response and almost no side effects.

ABSTRACT

Breast cancer is the most common female cancer in the world and in Poland. The improvement of diagnostic and therapeutic methods has led to patients’ longer life expectancy. It has also made breast cancer a chronic disease, increasing the risk of late side effects of oncological therapy. More cardiovascular diseases are diagnose in patients over 65 with an oncological history than in those without it and therefore much effort must be made to maximise effectiveness of the therapy with as few side effects as possible. The article presents two breast cancer patients treated with big doses of liposomal doxorubicin with a good response and almost no side effects.

POPRZEDNIE NUMERY